AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis (Gastro Journal)

The American Gastroenterological Association (AGA) has released updated guidelines for managing moderate-to-severe ulcerative colitis (UC), emphasizing advanced pharmacological therapies and personalized treatment approaches. The guidelines recommend using medications such as infliximab, vedolizumab, and upadacitinib over no treatment and suggest prioritizing higher-efficacy medications, particularly for patients naive to advanced therapies or with prior therapy failures. Combination therapy with TNF antagonists and immunomodulators is preferred, but withdrawal of TNF antagonists is discouraged for patients in sustained remission.